Much Anticipated JULIET Data Show Novartis Playing Catch-Up On CAR-T Manufacturing
Novartis reported positive early results for its lead CAR-T candidate CTL019 in DLBCL that appear to be consistent with Kite's competing therapy in the same indication, but the data show the Swiss big pharma ran into manufacturing issues that weren't resolved until later in the JULIET study.
You may also be interested in...
What's Gilead Getting From Kite For Nearly $12bn?
The $180 per share that Gilead's paying for CAR-T maker Kite was deemed too high by some and just right by others, but the big biotech expects a lot from its new cell therapy platform.
Kite First Off The Blocks For EU CAR-T Filing
Kite Pharma may have been pipped to the post to be first with a CAR-T product at the US FDA, but it has sneaked in the first EU filing courtesy of PRIME for axicabtagene ciloleucel.
More Than CAR-T: Hematologic Oncology Pipeline Offers Rich Menu Of Possible Approvals
Sponsors of established products like Amgen's Kyprolis and Blincyto and Bristol's Sprycel work to bulk up labeling with new indications while FDA reviews at least six novel agents for blood cancers.